ATHN Transcends is a study looking at blood disorders that are not cancerous (non-neoplastic). The goal is to understand how safe and effective different treatments are over time. Participants will be followed for at least 15 years in about 150 locations connected to the American Thrombosis and Hemostasis Network (ATHN). The study involves different groups called cohorts, like Hemophilia or Von Willebrand Disease, each with unique requirements.

• Study Duration: Participants are involved for a minimum of 15 years.
• Visits: Data is collected at the start, then quarterly, annually, and sometimes in between.
• Eligibility: Must have a blood disorder like Hemophilia or others listed, and be able to consent to the study.

Each cohort focuses on specific conditions. For example, the Hemophilia group studies treatments for types A and B of this condition. Some groups, like the Von Willebrand Disease or Rare Disorders, are not currently open for new participants. To join, you need to meet certain criteria and be willing to participate in study activities. There are no direct exclusions for most groups, but some require specific medical histories or conditions. Consider if you can commit to this long-term study before enrolling.